ChemoCentryx, Inc.
(NASDAQ GS: CCXI)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of ChemoCentryx, Inc. (“ChemoCentryx”) on behalf of stockholders. A class action complaint has been filed against ChemoCentryx. The complaint alleges that, between November 26, 2019 and May 6, 2021, defendants misrepresented and/or failed to disclose to investors that: (i) the study design of ChemoCentryx’s Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of the drug candidate avacopan and its role in the management of ANCA-associated vasculitis; (ii) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (iii) these issues presented a substantial concern regarding the viability of ChemoCentryx’s new drug application for avacopan for the treatment of ANCA-associated vasculitis; and (iv) as a result, defendants’ public statements were materially false and misleading.